An oral ETA-selective endothelin receptor antagonist for contrast nephropathy?

Nephrology Dialysis Transplantation

Volumn 16, Issue 7, 2001, Pages 1336-1337

  Haylor, John L ^a   Morcos, Sameh K ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; CONTRAST MEDIUM; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST;

CIRCULATION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION; NEPHROTOXICITY; NORMAL HUMAN; NOTE; PRIORITY JOURNAL; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE;

EID: 0034942568     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.7.1336     Document Type: Note

References (18)

1. Contrast media-induced nephrotoxicity-questions and answers
2. A primer in radiocontrast-induced nephropathy
3. Exacerbation of radio-contrast nephrotoxicity by endothelin receptor antagonism
4. Blockade of radiocontrast-induced nephrotoxicity by the endothelin antagonist, SB 209670
5. Effect of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors
6. Pharmacokinetics and pharmacodynamics of SB209670, an endothelin receptor antagonist: Effects on the regulation of renal vascular tone
7. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: A prospective randomised clinical trial
8. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration
9. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects
10. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans
11. Endothelin in human and canine radiocontrast nephropathy
12. Role of endothelin receptor subtypes in the systemic and renal responses to ET-1 in humans
13. Non-peptide endothelin receptor antagonists. VII: Binding characteristics of [3H] SB 209670, a novel nonpeptide antagonist of endothelin receptors
14. Radiocontrast media induced endothelin-1 mRNA expression and peptide release in porcine aortic endothelial cells
15. Bosentan, an orally active endothelin antagonist: Effect on the renal response to contrast media
16. The effect of an endothelin receptor antagonist bosentan on blood pressure in patients with essential hypertension
17. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
18. Bosentan in essential hypertension